Range Low Price High Price Comment
30 days $1.80 $1.80 Wednesday, 17th Aug 2022 GTXI stock ended at $1.80. During the day the stock fluctuated 0% from a day low at $1.80 to a day high of $1.80.
90 days $1.80 $1.80
52 weeks $1.62 $4.63

Historical GTx prices

Date Open High Low Close Volume
Aug 17, 2022 $1.80 $1.80 $1.80 $1.80 0
Aug 16, 2022 $1.80 $1.80 $1.80 $1.80 0
Aug 15, 2022 $1.80 $1.80 $1.80 $1.80 0
Aug 12, 2022 $1.80 $1.80 $1.80 $1.80 0
Aug 11, 2022 $1.80 $1.80 $1.80 $1.80 0
Aug 10, 2022 $1.80 $1.80 $1.80 $1.80 0
Aug 09, 2022 $1.80 $1.80 $1.80 $1.80 0
Aug 08, 2022 $1.80 $1.80 $1.80 $1.80 0
Aug 05, 2022 $1.80 $1.80 $1.80 $1.80 0
Aug 04, 2022 $1.80 $1.80 $1.80 $1.80 0
Aug 03, 2022 $1.80 $1.80 $1.80 $1.80 0
Aug 02, 2022 $1.80 $1.80 $1.80 $1.80 0
Aug 01, 2022 $1.80 $1.80 $1.80 $1.80 0
Jul 29, 2022 $1.80 $1.80 $1.80 $1.80 0
Jul 28, 2022 $1.80 $1.80 $1.80 $1.80 0
Jul 27, 2022 $1.80 $1.80 $1.80 $1.80 0
Jul 26, 2022 $1.80 $1.80 $1.80 $1.80 0
Jul 25, 2022 $1.80 $1.80 $1.80 $1.80 0
Jul 22, 2022 $1.80 $1.80 $1.80 $1.80 0
Jul 21, 2022 $1.80 $1.80 $1.80 $1.80 0
Jul 20, 2022 $1.80 $1.80 $1.80 $1.80 0
Jul 19, 2022 $1.80 $1.80 $1.80 $1.80 0
Jul 18, 2022 $1.80 $1.80 $1.80 $1.80 0
Jul 15, 2022 $1.80 $1.80 $1.80 $1.80 0
Jul 14, 2022 $1.80 $1.80 $1.80 $1.80 0
Click to get the best stock tips daily for free!

About GTx

GTx GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other serious medical conditions. The company is developing selective androgen receptor modulators to treat a range of serious diseases, including breast cancer, stress urinary incontinence, and Duchenne muscular dystrophy; and selective androgen receptor degrader for the trea... GTXI Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT